Previous 10 | Next 10 |
DiaMedica Therapeutics (NASDAQ: DMAC ): Q1 GAAP EPS of -$0.19 beats by $0.09 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
DM199 Met Primary Safety and Tolerability Endpoints in ReMEDy Study Top-Line Data Demonstrated Therapeutic Effect in Participants Not Pre-Treated With Mechanical Thrombectomy Reduced Risk of Recurrent Stroke Results Consistent With Clinical Studies of Approved Uri...
DM199 Met Primary Safety and Tolerability Endpoints in ReMEDy Study Top-Line Data Demonstrated Therapeutic Effect in Patients Not Pre-treated with Mechanical Thrombectomy DiaMedica Completes $8.5M Public Offering of Common Shares Cash and Investments of $12.6 Mill...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2020 financial results will be released after the markets close on Wednesday, May 13 th . DiaMedica will host a live conference call on Thursday, May 14 th at 7:00 AM Central Time to discuss its business update...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled “Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease ...
DiaMedica Therapeutics Inc. (DMAC) Q4 2019 Results Earnings Conference Call March 24, 2020, 8:00 am ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital ...
DiaMedica Therapeutics (NASDAQ: DMAC ): FY GAAP EPS of -$0.89 beats by $0.04 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment; Data Readout Expected in Q2 2020 Phase II Study of DM199 in Chronic Kidney Disease Ongoing; Steps Being Taken to Mitigate Potential Impact of COVID-19 Raised $8.5 Million in Gross Proceeds in Pu...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its fourth quarter 2019 financial results will be released after the markets close on Monday, March 23 rd . DiaMedica will host a live conference call on Tuesday, March 24 th at 7:00 AM Central Time to discuss its business updat...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will participate at the 32 nd Annual ROTH Conference The conference will be held from March 15-17, 2020 at The Ritz Carlton, Laguna Niguel, California. Mr. Pauls will also...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...